🇺🇸 Candonilimab in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 1
Most-reported reactions
- Disease Progression — 1 report (100%)
Other Other approved in United States
Frequently asked questions
Is Candonilimab approved in United States?
Candonilimab does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Candonilimab in United States?
Shi Ming is the originator. The local marketing authorisation holder may differ — check the official source linked above.